Johnson & Johnson (NYSE:JNJ) Shares Sold by Hancock Whitney Corp

Hancock Whitney Corp lessened its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 65,847 shares of the company’s stock after selling 238 shares during the period. Hancock Whitney Corp’s holdings in Johnson & Johnson were worth $10,757,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of JNJ. Morton Brown Family Wealth LLC lifted its stake in Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after acquiring an additional 78 shares during the period. Goodman Advisory Group LLC acquired a new position in Johnson & Johnson during the second quarter valued at $39,000. Cardinal Capital Management Inc. raised its stake in shares of Johnson & Johnson by 333.3% during the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after buying an additional 200 shares during the last quarter. First Bank & Trust lifted its holdings in shares of Johnson & Johnson by 69.6% in the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after buying an additional 156 shares during the period. Finally, Heritage Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the second quarter worth about $84,000. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the firm’s stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the sale, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Peter Fasolo sold 22,864 shares of the firm’s stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the sale, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 300,750 shares of company stock valued at $52,311,677. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Down 0.5 %

Shares of JNJ opened at $174.00 on Friday. The stock has a 50 day moving average price of $176.28 and a 200 day moving average price of $171.61. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The stock has a market capitalization of $454.92 billion, a price-to-earnings ratio of 24.23, a PEG ratio of 3.45 and a beta of 0.56. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $2.60 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.60%. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on JNJ shares. Sanford C. Bernstein decreased their price target on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Credit Suisse Group began coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target on the stock. Raymond James decreased their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Atlantic Securities dropped their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Finally, Barclays assumed coverage on Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target for the company. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $182.42.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.